SnET2 data

PDTI announced preliminary results of a Phase I/II study of the light-activated drug technology in 46 patients with 418 tumors caused by a variety of skin cancers.

All tumors responded to the treatment in metastatic adenocarcinomas, with 96 percent complete and 4 percent partial responses. ...